Biotechnology Today’s news of the licensing of Trodelvy (sacituzumab govitecan) brings little comfort to women with triple negative incurable secondary breast cancer, as the drug’s developer, company Gilead Sciences (Nasdaq: GILD), failed to reach an agreement with NHS England to provide the drug free-of-charge to eligible patients, ahead of a National Institute for Health cand Care Excellence (NICE) decision on routine National Health Service (NHS) access next year, says the charity Breast Cancer Now. 10 September 2021